N/A N=105 Incentivizing Behavior Change Skills to Promote Weight Loss
Obesity
Primary: Weight Change From Baseline to 24 Weeks — -8.046; -15.496; -12.167; -17.696 Pounds (lbs.)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=196 Improving Retreatment Success (IMPRESS)
Recurrent Tuberculosis
Primary: Sputum Culture Conversion Rates at Week 8 and Month 6 Post Tuberculosis Treatment Initiation — 78; 73; 84; 92 Participants — p=0.46
Phase 3 N=71 Isoflavones and the Coronary Circulation in Men and Women With Coronary Artery Disease
Coronary Artery Disease
Primary: Coronary Artery Diameter — 3.1; 2.7 mm
Phase 1 N=24 The Safety and Pharmacokinetics of Primapur and Gonal-f
Area Under Curve · Pharmacokinetics · Absorption
Primary: Area Under the Serum Concentration of Follicle Stimulating Hormone (FSH) - Time Curve (AUC(0-192)) — 1202.85; 1241.01 mIU*h/ml — p=0.05
N/A N=592 A Multi-center Trial of IMPaCT CHW Support for Chronically-ill Patients
Hypertension · Diabetes · Obesity
Primary: Short Form Health Survey (SF-12) Physical Component Score (PCS) — 2.3; 0.6 score on a scale — p=0.30
N/A N=60 A Study of the Safety and Effectiveness of JUVÉDERM VOLUMA® XC Injectable Gel for Cheek Augmentation Using Cannula
Age-related Volume Deficit in the Mid-face
Primary: Change From Baseline in Mid-Face Volume Deficit Scale (MFVDS) Score — 3.5; 3.5; -1.8; -1.9 score on a scale
N/A N=20 Effects of IV Administration of Ketamine on the Analgesia Nociception Index (ANI) Measured With the PhysioDoloris
Monitoring, Intraoperative
Primary: Mean ANI Changes After Intubation — 2.11 index
N/A N=40 Effect of Violent First-Person Shooter (FPS) Video Games on Shooting Accuracy
Gun Shot Wound
Primary: Hits to Head and Face — 132.7; 3.88; 5.33; 4.41 headshots — p=0.04
Phase 2 N=32 Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (Stage IIIB-IV)
Primary: Confirmed Complete Response (CR) Rate — 0; 0 patients (%)
Phase 1 N=24 The Pharmacokinetics of Gefapixant (MK-7264) in Participants With Renal Insufficiency (MK-7264-026)
Renal Insufficiency
Primary: [Parts 1 and 2] Mean Area Under the Concentration-Time Curve From Time Zero Up to Infinity (AUC0-inf) of Gefapixant 50 mg (Categorical Analysis) — 6450; 9970; 9990; 8590…
N/A N=285 RCT of Non-Invasive Vagus Nerve Stimulation (nVNS) With gammaCore®, for the Acute Treatment of Migraine Attacks
Migraine
Primary: Number of Participants With Treatment Response - No Pain — 36; 26 Participants
Phase 3 N=69 Safety and Efficacy of Etanercept (Recombinant Human Tumor Necrosis Factor Receptor Fusion Protein [TNFR:Fc]) in Children With Juvenile Rheumatoid Arthritis (JRA)
Juvenile Rheumatoid Arthritis
Primary: Percentage of Participants With Disease Flare in Part 2 — 81; 28 percentage of participants — p=0.0030
N/A N=162 Tumor: Breast Ratio Study
Breast Cancer · LCIS · DCIS
Primary: Quality of Life as Measured by the Breast Q — 61.9; 57.6; 74.2; 64.2 score on a scale
Early Phase 1 N=32 Premature Fatigue in Veterans With Heart Failure: Neuronal Influences
Heart Failure
Primary: Maximal Voluntary Quadriceps Force [% Change From Baseline] — -30; -5 percentage change
N/A N=40 iStart Smart for Teens for Healthy Weight Management
Overweight · Obese
Primary: Body Mass Index (BMI) — 27.37; 28.35; 26.93; 29.18 kg/m^2 — p=<.001